10X Genomics Inc
TXG12.640USD
-0.110-0.86%
Close 10/06, 16:00（ET）Quotes delayed by 15 min
1.57BMarket Cap
LossP/E TTM
More Details of 10X Genomics Inc Company
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
10X Genomics Inc Info
Ticker SymbolTXG
Company name10X Genomics Inc
IPO dateSep 12, 2019
CEOMr. Serge Wilson Saxonov, Ph.D.
Number of employees1306
Security typeOrdinary Share
Fiscal year-endSep 12
Address6230 Stoneridge Mall Road
CityPLEASANTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94588
Phone19254017300
Websitehttps://www.10xgenomics.com/
Ticker SymbolTXG
IPO dateSep 12, 2019
CEOMr. Serge Wilson Saxonov, Ph.D.
Company Executives of 10X Genomics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.06M
-0.09%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+4.34%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+29.09%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+34.83%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
44.69K
-14.35%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+115.82%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
28.62K
+115.82%
Mr. Adam S. Taich
Mr. Adam S. Taich
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alan V. Mateo
Mr. Alan V. Mateo
Independent Director
Independent Director
--
--
Dr. Sarah A. Teichmann
Dr. Sarah A. Teichmann
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.06M
-0.09%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+4.34%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+29.09%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+34.83%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
44.69K
-14.35%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+115.82%
Revenue Breakdown
Currency: USDUpdated: 7 hours ago
Currency: USDUpdated: 7 hours ago
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Consumables
122.19M
70.66%
Products and services revenue
27.75M
16.05%
Instruments
14.50M
8.38%
Services
8.47M
4.90%
By RegionUSD
Name
Revenue
Proportion
United States
103.49M
59.85%
Europe, the Middle East and Africa
34.73M
20.09%
China
23.17M
13.40%
Asia Pacific
8.85M
5.12%
Americas
2.67M
1.54%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
122.19M
70.66%
Products and services revenue
27.75M
16.05%
Instruments
14.50M
8.38%
Services
8.47M
4.90%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
12.14%
The Vanguard Group, Inc.
10.85%
Fidelity Management & Research Company LLC
6.68%
BlackRock Institutional Trust Company, N.A.
6.63%
Sumitomo Mitsui Trust Bank, Limited
5.26%
Other
58.44%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
12.14%
The Vanguard Group, Inc.
10.85%
Fidelity Management & Research Company LLC
6.68%
BlackRock Institutional Trust Company, N.A.
6.63%
Sumitomo Mitsui Trust Bank, Limited
5.26%
Other
58.44%
Shareholder Types
Shareholders
Proportion
Investment Advisor
53.51%
Investment Advisor/Hedge Fund
22.37%
Hedge Fund
14.10%
Bank and Trust
6.38%
Research Firm
4.97%
Venture Capital
2.31%
Individual Investor
1.85%
Pension Fund
0.63%
Family Office
0.51%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
662
119.53M
104.47%
-16.69M
2025Q2
669
120.42M
108.39%
-15.20M
2025Q1
687
115.67M
104.27%
-8.84M
2024Q4
689
107.08M
98.92%
-12.41M
2024Q3
682
106.90M
100.39%
-9.08M
2024Q2
691
105.36M
99.70%
-5.09M
2024Q1
762
106.36M
101.17%
-3.12M
2023Q4
817
100.80M
96.01%
-9.73M
2023Q3
835
96.86M
93.80%
-12.55M
2023Q2
857
94.98M
96.77%
-15.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
13.89M
12.14%
+1.05M
+8.15%
Jun 30, 2025
The Vanguard Group, Inc.
12.42M
10.85%
+1.32M
+11.92%
Jun 30, 2025
Fidelity Management & Research Company LLC
7.64M
6.68%
-930.78K
-10.85%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
7.58M
6.63%
+2.17M
+40.18%
Jun 30, 2025
Sumitomo Mitsui Trust Bank, Limited
6.02M
5.26%
+654.60K
+12.20%
Jun 30, 2025
AQR Capital Management, LLC
4.14M
3.62%
+2.93M
+241.28%
Jun 30, 2025
BofA Global Research (US)
2.91M
2.54%
+350.99K
+13.74%
Jun 30, 2025
Millennium Management LLC
2.88M
2.52%
-2.65M
-47.89%
Jun 30, 2025
Two Sigma Investments, LP
2.84M
2.48%
-329.64K
-10.40%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.65M
2.32%
+773.20K
+41.18%
Jun 30, 2025
View more
Related ETFs
Updated: 16 hours ago
Updated: 16 hours ago
Name
Proportion
ARK Genomic Revolution ETF
4.36%
WisdomTree BioRevolution Fund
2.19%
Global X Genomics & Biotechnology ETF
1.7%
Janus Henderson Small Cap Growth Alpha ETF
1.61%
ARK Innovation ETF
1.38%
Harbor Long-Short Equity ETF
1.06%
Invesco NASDAQ Future Gen 200 ETF
0.59%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.51%
Principal U.S. Small-Cap ETF
0.22%
Vanguard US Quality Factor ETF
0.16%
View more
ARK Genomic Revolution ETF
Proportion4.36%
WisdomTree BioRevolution Fund
Proportion2.19%
Global X Genomics & Biotechnology ETF
Proportion1.7%
Janus Henderson Small Cap Growth Alpha ETF
Proportion1.61%
ARK Innovation ETF
Proportion1.38%
Harbor Long-Short Equity ETF
Proportion1.06%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.59%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.51%
Principal U.S. Small-Cap ETF
Proportion0.22%
Vanguard US Quality Factor ETF
Proportion0.16%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
